Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
442
-
Total 13F shares, excl. options
-
59.5M
-
Shares change
-
+1.86M
-
Total reported value, excl. options
-
$3.21B
-
Value change
-
+$82.3M
-
Put/Call ratio
-
1.07
-
Number of buys
-
194
-
Number of sells
-
-197
-
Price
-
$54.01
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q2 2024
558 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q2 2024.
CRISPR Therapeutics AG - Common Stock (CRSP) has 442 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.5M shares
of 86M outstanding shares and own 69.2% of the company stock.
Largest 10 shareholders include Capital International Investors (7.87M shares), ARK Investment Management LLC (7.78M shares), Nikko Asset Management Americas, Inc. (3.15M shares), Sumitomo Mitsui Trust Holdings, Inc. (3.15M shares), BlackRock Inc. (2.78M shares), T. Rowe Price Investment Management, Inc. (2.73M shares), STATE STREET CORP (2.39M shares), FMR LLC (2.35M shares), VANGUARD GROUP INC (1.75M shares), and NEA Management Company, LLC (1.59M shares).
This table shows the top 442 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.